FDA Greenlights Two New HER2-Targeted Lung Cancer Drugs in Recent Months

HER2-mutant non-small cell lung cancer has long been an underserved niche in thoracic oncology. Unlike HER2-amplified breast cancer, HER2 tyrosine kinase domain mutations in lung cancer were historically treated with chemotherapy or immunotherapy with modest results. The recent wave of FDA accelerated approvals signals a turning point for this patient population.

Zongertinib (Hernexeos) was first granted accelerated approval in August 2025 for unresectable or metastatic non-squamous NSCLC with HER2 TKD activating mutations after prior therapy. A second, broader approval followed in February 2026, expanding eligibility to adults with unresectable or metastatic disease detected by an FDA-authorized companion diagnostic test. This dual-approval trajectory suggests strong early clinical data supporting its use across treatment lines.

Sevabertinib (Hyrnuo) received its accelerated approval in November 2025, targeting the same HER2 TKD mutation-positive NSCLC population in the post-prior-therapy setting. The availability of two distinct agents in this space introduces the possibility of sequencing or comparing these therapies, which will be an important area for future clinical investigation.

Both approvals are accelerated, meaning they are based on surrogate endpoints — typically objective response rate and duration of response — rather than overall survival. Confirmatory trials are required to verify clinical benefit. Physicians should note that patient selection depends on companion diagnostic testing, making molecular profiling of tumor tissue or liquid biopsy essential before prescribing.

For the broader longevity and cancer-prevention audience, these approvals underscore the accelerating pace of precision oncology. Identifying actionable mutations early through routine molecular testing is increasingly critical. As HER2-targeted options expand in lung cancer, the case for comprehensive genomic profiling at diagnosis grows stronger for all advanced NSCLC patients.